← Back to search

Protein Structures and Oligomeric States

Enter a protein name, UniProt accession or PDB ID. Name searches ask you to confirm the protein identity before related structures are queried.

Current Protein Identity：P35991 New Search
14PDB entries
18Biological assembly
20chain/assembly records
Main Difference Dimensions in This Set
Different construct Different mutation/modification Different assembly state Different ligand/ion Different experimental conditions Different structure-quality metrics

Difference tags compare only the current result set; every original PDB and assembly record remains separate.

Related-Structure Differences

Each row represents one biological assembly in one PDB entry; multiple monomers of the same protein are listed separately.

PDB Entry Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Experimental Method Experimental Conditions Structure Quality
4XI2 Crystal Structure of an auto-inhibited form of Bruton's Tryrosine Kinase Deposited 2015-01-06 Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count
Chain A 214–659（446 aa） Fragment：UNP residues 214-659
Not recorded AU GOLD ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；Mix purified dimer protein at 5 mg/ml in 25 mM TRIS.Cl, pH 8.5, 10 mM NaCl, 5 mM DTT with an equal volume of the precipitant solution, 100 mM TRIS.Cl, pH 8.5, 200 mM Na.acetate, 7.5 % PEG 4,000, then suspend over 1 ml of precipitant solution. Wedge shaped crystals grew to approximately 0.1 mm on a side after a period of two weeks. Crystals were frozen by first transferring them, in four sequential steps, to a solution of 100 mM TRIS.Cl, pH 8.5, 200 mM Na.acetate, 15 % PEG 4,000. This was followed by transfer in six sequential steps to a solution containing 100 mM TRIS.Cl, pH 8.5, 200 mM Na.acetate, 15 % PEG 4,000, 30% glucose
Resolution 2.60 Å R-free 0.248
8FD9 Structure of BTK kinase domain with the second-generation inhibitor acalabrutinib Deposited 2022-12-02 Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain A 396–659（264 aa）
Mutation：K430R, L542M S543T, V555T, R562K, S564A, P565S, Y617P XQQ 4-[(4S)-8-amino-3-{(2S)-1-[(2E)-but-2-enoyl]pyrrolidin-2-yl}imidazo[1,5-a]pyrazin-1-yl]-N-(pyridin-2-yl)benzamide × 1 BR BROMIDE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 6.5；277 K；20% PEG 3350, 0.1M Bis-tris propane, pH 6.5 and 0.2M sodium bromide
Resolution 1.70 Å R-free 0.228
8FF0 Structure of BTK kinase domain with the second-generation inhibitor tirabrutinib Deposited 2022-12-07 Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain A 396–659（264 aa）
Mutation：K430R, L542M S543T, V555T, R562K, S564A, P565S, Y617P 7GB 6-azanyl-9-[(3~{R})-1-[(~{E})-but-2-enoyl]pyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；277 K；16% PEG 8000 and 0.1M sodium citrate
Resolution 2.60 Å R-free 0.267
8GMB Crystal structure of the full-length Bruton's tyrosine kinase (PH-TH domain not visible) Deposited 2023-03-24 Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count
Chain A 1–659（659 aa）
Mutation：E298A, K300A, E301A, A384P, S386P, T387P, A388P, L390F, K430R, L542M S543T, V555T, R562K, S564A, P565S, Y617P 9AJ 2-[3'-(hydroxymethyl)-1-methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo[1,6-dihydro[3,4'-bipyridine]]-2'-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.5；277.15 K；20% PEG 3350, 0.1M Bis-Tris Propane, 0.2M potassium thiocyanate
Resolution 3.40 Å R-free 0.289
8S93 Crystal structure of the PH-TH/kinase complex of Bruton's tyrosine kinase Deposited 2023-03-27 Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain A 1–171（171 aa） Fragment：PHTH domain residues 1-171 and Kinase domain residues 396-659
Chain A 396–659（264 aa） Fragment：PHTH domain residues 1-171 and Kinase domain residues 396-659
Mutation：Q91A, I92A, I94A, I95A, K430R, L542M S543T, V555T, R562K, S564A, P565S, Y617P Mutation：Q91A, I92A, I94A, I95A, K430R, L542M S543T, V555T, R562K, S564A, P565S, Y617P 9AJ 2-[3'-(hydroxymethyl)-1-methyl-5-({5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl}amino)-6-oxo[1,6-dihydro[3,4'-bipyridine]]-2'-yl]-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one × 1 ZN ZINC ION × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 5.6；277 K；20%PEG3350, 0.1M Bis-Tris, pH5.6, 0.2M magnesium chloride
Resolution 2.10 Å R-free 0.246
8S9F Crystal structure of the kinase domain of Bruton's Tyrosine Kinase bound to dasatinib Deposited 2023-03-28 Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count
Chain A 382–659（278 aa）
Chain B 382–659（278 aa）
Mutation：L390G, Y551E, Y617P Mutation：L390G, Y551E, Y617P 1N1 N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；42% PEG200, 0.1M HEPES
Resolution 2.60 Å R-free 0.284
9EJJ Bruton's tyrosine kinase in complex with compound PTI55 Deposited 2024-11-28 Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain A 382–659（278 aa）
Mutation：L390G, Y551E, Y617P A1BIZ 4-{4-amino-1-[(3R)-1-(cyclopropanecarbonyl)piperidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-N-[4-(trifluoromethoxy)pyridin-2-yl]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.1M NaCitrate pH 5.5, 18% PEG3350
Resolution 2.03 Å R-free 0.242
9EJJ Bruton's tyrosine kinase in complex with compound PTI55 Deposited 2024-11-28 Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain B 382–659（278 aa）
Mutation：L390G, Y551E, Y617P A1BIZ 4-{4-amino-1-[(3R)-1-(cyclopropanecarbonyl)piperidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-N-[4-(trifluoromethoxy)pyridin-2-yl]benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.1M NaCitrate pH 5.5, 18% PEG3350
Resolution 2.03 Å R-free 0.242
9EJR Bruton's tyrosine kinase in complex with compound PTI52 Deposited 2024-11-28 Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain A 382–659（278 aa）
Mutation：L390G, Y551E, Y617P A1BI0 4-{4-amino-1-[(3R)-1-(cyclopropanecarbonyl)piperidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-N-(4-cyclopropylpyridin-2-yl)benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.1M NaCitrate pH 5.5, 18% PEG3350
Resolution 2.10 Å R-free 0.295
9EJR Bruton's tyrosine kinase in complex with compound PTI52 Deposited 2024-11-28 Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain B 382–659（278 aa）
Mutation：L390G, Y551E, Y617P A1BI0 4-{4-amino-1-[(3R)-1-(cyclopropanecarbonyl)piperidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-N-(4-cyclopropylpyridin-2-yl)benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.1M NaCitrate pH 5.5, 18% PEG3350
Resolution 2.10 Å R-free 0.295
9EJS Bruton's tyrosine kinase with mutations in the activation loop in complex with compound PTI52 Deposited 2024-11-28 Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain A 396–659（264 aa）
Mutation：K430R, L542M, S543T, V555T, R562K, S564A, P565S A1BI0 4-{4-amino-1-[(3R)-1-(cyclopropanecarbonyl)piperidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-N-(4-cyclopropylpyridin-2-yl)benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；Sodium citrate tribasic dihydrate pH 5.5, 16% w/v Polyethylene glycol 8,000
Resolution 2.26 Å R-free 0.246
9EJS Bruton's tyrosine kinase with mutations in the activation loop in complex with compound PTI52 Deposited 2024-11-28 Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain B 396–659（264 aa）
Mutation：K430R, L542M, S543T, V555T, R562K, S564A, P565S A1BI0 4-{4-amino-1-[(3R)-1-(cyclopropanecarbonyl)piperidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-N-(4-cyclopropylpyridin-2-yl)benzamide × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；Sodium citrate tribasic dihydrate pH 5.5, 16% w/v Polyethylene glycol 8,000
Resolution 2.26 Å R-free 0.246
9EJS Bruton's tyrosine kinase with mutations in the activation loop in complex with compound PTI52 Deposited 2024-11-28 Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain C 396–659（264 aa）
Mutation：K430R, L542M, S543T, V555T, R562K, S564A, P565S A1BI0 4-{4-amino-1-[(3R)-1-(cyclopropanecarbonyl)piperidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-N-(4-cyclopropylpyridin-2-yl)benzamide × 1 DMS DIMETHYL SULFOXIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；Sodium citrate tribasic dihydrate pH 5.5, 16% w/v Polyethylene glycol 8,000
Resolution 2.26 Å R-free 0.246
9EJX Bruton's tyrosine kinase with mutations in the activation loop in complex with compound PTI42 Deposited 2024-11-29 Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain A 396–659（264 aa）
Mutation：K430R, L542M, S543T, V555T, R562K, S564A, P565S,Y617P A1BI1 {(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl}(cyclopropyl)methanone × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.1 M Sodium citrate tribasic dihydrate pH 5.5, 18% w/v Polyethylene glycol 8,000
Resolution 2.86 Å R-free 0.296
9ME2 Bruton's tyrosine kinase with mutations in the activation loop in complex with compound A110162 Deposited 2024-12-05 Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain A 396–659（264 aa）
Mutation：K430R, L542M, S543T, V555T, R562K, S564A, P565S,Y617P A1BKW 3-(4-phenoxyphenyl)-1-[(3S)-piperidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.1 M Sodium citrate tribasic dihydrate pH 5.5, 18% w/v Polyethylene glycol 8,000
Resolution 3.38 Å R-free 0.286
9ME3 Bruton's tyrosine kinase with mutations in the activation loop in complex with compound P301390 Deposited 2024-12-06 Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain A 396–659（264 aa）
Mutation：K430R, L542M, S543T, V555T, R562K, S564A, P565S,Y617P A1BJE 3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；277 K；0.1 M Sodium citrate tribasic dihydrate pH 5.5, 18% w/v Polyethylene glycol 8,000
Resolution 3.05 Å R-free 0.288
9ZLJ Crystal structure of BTK kinase domain bound to compound YS1 Deposited 2025-12-08 Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain A 382–659（278 aa）
Mutation：Y617P A1C20 N-{(1r,4r)-4-[2-(4-chlorophenoxy)acetamido]cyclohexyl}-N-[2-(4-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)ethyl]propanamide × 1 IMD IMIDAZOLE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；277 K；15-25% PEG3350, 0.1M imidazole
Resolution 1.60 Å R-free 0.218
9ZLM Crystal structure of BTK kinase domain bound to compound YS2 Deposited 2025-12-08 Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain A 382–659（278 aa）
Mutation：Y617P A1C2Z N-[4-(3-{2-oxo-2-[3-(phenoxymethyl)azetidin-1-yl]acetamido}phenyl)oxan-4-yl]propanamide × 1 IMD IMIDAZOLE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；277 K；15-25% PEG3350, 0.1M imidazole
Resolution 1.27 Å R-free 0.212

This page presents structural evidence recorded in PDB/mmCIF.“No recorded non-water small molecule” does not prove that the experimental sample was ligand-free; experimental conditions belong to the PDB experiment, while ligands and copy counts are shown for each biological assembly.